Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Allergan Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Notes payable 0.58 0.53 0.53 0.99 0.34
Convertible notes 0.00 0.00 0.00 0.00 7.73
Accounts payable 2.31 2.68 2.54 2.36 2.68
Accrued compensation 2.36 2.54 2.44 2.36 2.20
Sales rebates and other incentive programs 3.00 2.64 2.95 2.93 2.24
Royalties 0.22 0.25 0.28 0.32 0.42
Interest 0.18 0.21 0.20 0.18 0.21
Sales returns, specialty pharmaceutical products 0.49 0.53 0.54 0.44 0.35
Legal settlement expenses 0.00 0.00 0.00 0.00 0.18
Product warranties, breast implant products 0.06 0.07 0.07 0.08 0.08
Contingent consideration 0.43 0.09 0.64 0.06 0.00
Investment bank advisory fees 0.19 0.00 0.00 0.00 0.00
Annual branded prescription drug fee 0.27 0.06 0.00 0.00 0.00
Restructuring charges 0.88 0.00 0.00 0.00 0.00
Other 1.56 1.80 1.73 1.53 1.77
Other accrued expenses 7.29% 5.65% 6.42% 5.52% 5.26%
Income taxes 0.00 0.37 0.00 0.00 0.19
Current liabilities 12.54% 11.77% 11.93% 11.22% 18.40%
Long-term debt, excluding current maturities 16.80 19.84 16.48 17.81 18.47
Postretirement benefit plan 0.46 0.42 0.51 0.49 0.68
Qualified and non-qualified pension plans 2.15 1.84 2.38 2.40 1.83
Deferred executive compensation 0.94 1.00 0.93 0.88 0.83
Deferred income 0.59 0.63 0.82 0.95 1.06
Contingent consideration 2.51 2.04 1.80 2.46 0.50
Product warranties, breast implant products 0.23 0.25 0.30 0.31 0.28
Unrecognized tax benefit liabilities 0.67 0.64 0.59 0.46 0.19
Other 0.60 0.40 0.40 0.34 0.22
Other liabilities 8.14% 7.21% 7.72% 8.30% 5.59%
Non-current liabilities 24.93% 27.05% 24.20% 26.11% 24.06%
Total liabilities 37.47% 38.82% 36.13% 37.33% 42.45%
Preferred stock, $.01 par value; none issued 0.00 0.00 0.00 0.00 0.00
Common stock, $.01 par value 0.02 0.03 0.03 0.04 0.04
Additional paid-in capital 27.01 28.68 31.60 32.46 33.89
Accumulated other comprehensive loss -3.29 -2.14 -2.66 -2.84 -1.84
Retained earnings 47.48 43.94 41.75 34.90 26.79
Treasury stock, at cost -8.78 -9.39 -7.13 -2.15 -1.61
Total Allergan, Inc. stockholders’ equity 62.45% 61.12% 63.59% 62.40% 57.27%
Noncontrolling interest 0.08 0.06 0.28 0.27 0.28
Total equity 62.53% 61.18% 63.87% 62.67% 57.55%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan Inc. current liabilities as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 exceeding 2012 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current liabilities as a percentage of total liabilities and equity increased from 2012 to 2013 but then slightly decreased from 2013 to 2014 not reaching 2012 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan Inc. total liabilities as a percentage of total liabilities and equity increased from 2012 to 2013 but then slightly decreased from 2013 to 2014 not reaching 2012 level.
Total Allergan, Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan Inc. total Allergan, Inc. stockholders’ equity as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 not reaching 2012 level.